Lumipulse^® G ADxPLORER^® DDC

Dopa decarboxylase (DDC) is an essential enzyme in neurotransmitter metabolism, that catalyzes the conversion of L-DOPA into dopamine. Dysregulation of DDC activity has been implicated in neurodegenerative diseases, in particular DLB and Parkinson’s disease, reflecting its importance in dopaminergic pathways. In cerebrospinal fluid (CSF), DDC has recently emerged as a promising biomarker of dopaminergic dysfunction, with elevated levels reported in patients with dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)^1,2,3,4,5. However, its clinical utility remains to be further established.

The Lumipulse® G ADxPLORER® DDC assay was developed using a proprietary DDC monoclonal antibody ADx411 (90583) in conjunction with an alkaline phosphatase-conjugated Fab fragment derived from the ADx412 mAb (90584). The assay is calibrated with recombinant DDC full-length protein.
 

References:

1. Del Campo et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease. Nat Commun. 2023 Sep 13;14(1):5635.
2. Pereira et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023 Oct;3(10):1201-1209.
3. Rutledge et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease. Acta Neuropathol. 2024 Mar 11;147(1):52.
4. Appleton et al. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease. Transl Neurodegener. 2024 Jun 11;13(1):31.
5. Bolsewig et al. A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders. Nat Med 32, 1073–1084 (2026).

 
Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV.